Jeremy M Shefner

List of Publications by Year
in descending order

65 papers	3,551 citations	201674 27 h-index	149698 56 g-index
65 all docs	65 docs citations	65 times ranked	3570 citing authors

#	Article	IF	Citations
1	Prescription and acceptance of durable medical equipment in FORTITUDE-ALS, a study of reldesemtiv in ALS: post hoc analyses of a randomized, double-blind, placebo-controlled clinical trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 263-270.	1.7	2
2	Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. Brain, 2022, 145, 27-44.	7.6	38
3	Phase <scp>2B</scp> randomized controlled trial of <scp>NP001</scp> in amyotrophic lateral sclerosis: Preâ€specified and post hoc analyses. Muscle and Nerve, 2022, 66, 39-49.	2.2	16
4	Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 871-875.	1.9	37
5	A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 287-299.	1.7	42
6	Longâ€term survival of participants in the <scp>CENTAUR</scp> trial of sodium phenylbutyrateâ€taurursodiol in <scp>amyotrophic lateral sclerosis</scp>. Muscle and Nerve, 2021, 63, 31-39.	2.2	115
7	Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 186.	9.0	79
8	Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nature Reviews Neurology, 2021, 17, 104-118.	10.1	152
9	Putting the patient first: The validity and value of surface-based electrical impedance myography techniques. Clinical Neurophysiology, 2021, 132, 1752-1753.	1.5	9
10	Noninvasive ventilation use by patients enrolled in VITALITY-ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 1-9.	1.7	0
11	Evaluation of Amyotrophic Lateral Sclerosis-Induced Muscle Degeneration Using Magnetic Resonance-Based Relaxivity Contrast Imaging (RCI). Tomography, 2021, 7, 169-179.	1.8	1
12	Tocilizumab is safe and tolerable and reduces <scp>C</scp>â€reactive protein concentrations in the plasma and cerebrospinal fluid of <scp>ALS</scp> patients. Muscle and Nerve, 2021, 64, 309-320.	2.2	27
13	Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial. Muscle and Nerve, 2021, 63, 371-383.	2.2	13
14	Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design. Neurology: Clinical Practice, 2021, 11, e472-e479.	1.6	0
15	Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 15-23.	1.7	12
16	Trial of Sodium Phenylbutyrateâ€“Taurursodiol for Amyotrophic Lateral Sclerosis. New England Journal of Medicine, 2020, 383, 919-930.	27.0	299
17	Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 1883-1897.	3.7	16
18	Expression and Cellular Distribution of P-Glycoprotein and Breast Cancer Resistance Protein in Amyotrophic Lateral Sclerosis Patients. Journal of Neuropathology and Experimental Neurology, 2020, 79, 266-276.	1.7	17

#	Article	IF	Citations
19	ALS clinical research learning institutes (ALS-CRLI): empowering people with ALS to be research ambassadors. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 216-221.	1.7	5
20	Seven-Year Experience From the National Institute of Neurological Disorders and Strokeâ€“Supported Network for Excellence in Neuroscience Clinical Trials. JAMA Neurology, 2020, 77, 755.	9.0	6
21	A proposal for new diagnostic criteria for ALS. Clinical Neurophysiology, 2020, 131, 1975-1978.	1.5	268
22	Clinical neurophysiology of anterior horn cell disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 161, 317-326.	1.8	3
23	ALS drug development guidances and trial guidelines. Neurology, 2019, 93, 66-71.	1.1	19
24	Objective Assessment of Vocal Tremor. , 2019, 2019, 6386-6390.		3
25	Nusinersen in later-onset spinal muscular atrophy. Neurology, 2019, 92, e2492-e2506.	1.1	183
26	ALS longitudinal studies with frequent data collection at home: study design and baseline data. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 61-67.	1.7	42
27	VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 259-266.	1.7	21
28	Respiratory measures in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 321-330.	1.7	44
29	Profile of medical care costs in patients with amyotrophic lateral sclerosis in the Medicare programme and under commercial insurance. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 134-142.	1.7	18
30	Reducing sample size requirements for future ALS clinical trials with a dedicated electrical impedance myography system. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 555-561.	1.7	37
31	Relationships between slow vital capacity and measures of respiratory function on the ALSFRS-R. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 506-512.	1.7	7
32	An Appraisal of Novel Biomarkers for Evaluating and Monitoring Neurologic Diseases: Editorial Introduction. Neurotherapeutics, 2017, 14, 1-3.	4.4	8
33	Strength Testing in Motor Neuron Diseases. Neurotherapeutics, 2017, 14, 154-160.	4.4	29
34	Quantitative strength testing in ALS clinical trials. Neurology, 2016, 87, 617-624.	1.1	37
35	Reply. Annals of Neurology, 2016, 79, 334-334.	5.3	2
36	A randomized trial of mexiletine in ALS. Neurology, 2016, 86, 1474-1481.	1.1	72

#	Article	IF	Citations
37	Preclinical rodent toxicity studies for long term use of ceftriaxone. Toxicology Reports, 2015, 2, 1396-1403.	3.3	7
38	Safety, Pharmacokinetic, and Functional Effects of the Nogo-A Monoclonal Antibody in Amyotrophic Lateral Sclerosis: A Randomized, First-In-Human Clinical Trial. PLoS ONE, 2014, 9, e97803.	2.5	45
39	Quantifying disease progression in amyotrophic lateral sclerosis. Annals of Neurology, 2014, 76, 643-657.	5.3	133
40	Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2014, 13, 1083-1091.	10.2	187
41	Assessment of disease progression and functional benefit in neurodegenerative disease: Can we tell the difference?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 337-343.	1.7	1
42	A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 574-581.	1.7	34
43	The relationship between tirasemtiv serum concentration and functional outcomes in patients with ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 582-585.	1.7	12
44	Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 430-438.	2.1	33
45	Statistical motor unit number estimation and ALS trials: the effect of motor unit instability. Supplements To Clinical Neurophysiology, 2009, 60, 135-141.	2.1	8
46	Recent MUNE studies in animal models of motor neuron disease. Supplements To Clinical Neurophysiology, 2009, 60, 203-208.	2.1	4
47	Phase 2 study of sodium phenylbutyrate in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 99-106.	2.1	135
48	Muscle as a therapeutic target in amyotrophic lateral sclerosis. Experimental Neurology, 2009, 219, 373-375.	4.1	3
49	Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle and Nerve, 2008, 38, 837-844.	2.2	104
50	Electrodiagnostic criteria for diagnosis of ALS. Clinical Neurophysiology, 2008, 119, 497-503.	1.5	927
51	Designing Clinical Trials in Amyotrophic Lateral Sclerosis. Physical Medicine and Rehabilitation Clinics of North America, 2008, 19, 495-508.	1.3	17
52	Commentary on â€˜A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALSâ€™. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 254-256.	2.1	4
53	Creatine as a Potential Treatment for Amyotrophic Lateral Sclerosis. Progress in Neurotherapeutics and Neuropsychopharmacology, 2006, 1, 79-90.	0.0	0
54	Motor unit number estimation predicts disease onset and survival in a transgenic mouse model of amyotrophic lateral sclerosis. Muscle and Nerve, 2006, 34, 603-607.	2.2	47

#	Article	IF	Citations
55	Multi-drug therapy in amyotrophic lateral sclerosis: Combinations of multiple, untested drugs should not be used at this time. Muscle and Nerve, 2004, 30, 676-678.	2.2	3
56	Measures and markers in Amyotrophic Lateral Sclerosis. Neurotherapeutics, 2004, 1, 273-283.	4.4	0
57	Motor unit number estimation. Physical Medicine and Rehabilitation Clinics of North America, 2003, 14, 243-260.	1.3	32
58	Motor Unit Number Estimation: Summary. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2002, 3, S97-S102.	1.2	0
59	Comparison of incremental with multipoint MUNE methods in transgenic ALS mice. Muscle and Nerve, 2002, 25, 39-42.	2.2	56
60	Motor unit number estimation in neurologic disease. Advances in Neurology, 2002, 88, 33-52.	0.8	12
61	The use of non-invasive positive pressure ventilation (NIPPV) in ALS patients. A need for improved determination of intervention timing. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2001, 2, 139-145.	1.2	25
62	Reproducibility of motor unit number estimation in individual subjects. Muscle and Nerve, 2001, 24, 467-473.	2.2	35
63	Excitability testing in clinical neurophysiology?what, why, and when?. Muscle and Nerve, 2001, 24, 845-847.	2.2	7
64	Creatine as a potential treatment for amyotrophic lateral sclerosis. , 0, , 79-90.		0
65	Changing ALS Diagnostic Criteria: Will it Impact Clinical Trials?. Muscle and Nerve, 0, , .	2.2	1